论文部分内容阅读
目的分析替比夫定和恩替卡韦治疗代偿期乙型肝炎肝硬化的临床疗效。方法选取2013年8月至2014年8月本院收治的代偿期乙型肝炎肝硬化患者60例,按照不同给药方法分为观察组与对照组,每组30例。对照组患者恩替卡韦治疗,观察组患者替比夫定治疗,记录并分析相关数据。结果两组治疗48周后肝功能和肝纤维化水平均低于治疗前,差异均具统计学意义(P<0.05)。结论替比夫定和恩替卡韦治疗代偿期乙型肝炎肝硬化的临床疗效相当。
Objective To analyze the clinical efficacy of telbivudine and entecavir in the treatment of decompensated hepatitis B cirrhosis. Methods Sixty patients with decompensated hepatitis B cirrhosis admitted from August 2013 to August 2014 in our hospital were divided into observation group and control group according to different administration methods, 30 cases in each group. The patients in the control group were treated with entecavir, and the patients in the observation group were treated with telbivudine. The relevant data were recorded and analyzed. Results The liver function and liver fibrosis of the two groups after 48 weeks of treatment were lower than those before treatment, the differences were statistically significant (P <0.05). Conclusion The clinical efficacy of telbivudine and entecavir in the treatment of decompensated hepatitis B cirrhosis is comparable.